Advancing early disease detection and precision medicine with breath-based diagnostics

Billy Boyle, co-founder and CEO of Owlstone Medical, discusses pioneering diagnostics using breath analysis to improve patient outcomes through early disease detection. Owlstone Medical’s proprietary breath biopsy technology employs exogenous probes—targeted compounds inhaled or ingested—to detect disease-specific biomarkers in exhaled breath. This innovative approach aims to save lives and reduce healthcare costs by facilitating early diagnosis and enabling precision medicine in areas like cancer, liver disease, and digestive disease. Collaboration with clinical and academic partners supports further validation and application of this breakthrough technology.

This interview was recorded for #CLINICAL24 2024